Clinical trials for Neurofibromatosis type 1
30 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGN/ANCT06507748A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)National Cancer Institute (NCI) · PI: Pamela L Wolters, Ph.D.
- RECRUITINGPhase 1NCT07102394Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1Johns Hopkins University · PI: Carlos Romo, MD
- RECRUITINGN/ANCT07221331Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)AstraZeneca · PI: AstraZeneca Clinical Study Information Center
- RECRUITINGN/ANCT07088991Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsiaAstraZeneca · PI: AstraZeneca Clinical Study Information Center
- RECRUITINGPhase 1NCT06961565PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform NeurofibromasPasithea Therapeutics Corp. · PI: Tiago R Marques, MD
- RECRUITINGN/ANCT06880991Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative StudyNational Cancer Institute (NCI) · PI: Staci M Peron, Ph.D.
- RECRUITINGPhase 2NCT06541847A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1Healx Limited · PI: Miriam Bornhorst
- RECRUITINGN/ANCT06222203Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)National Cancer Institute (NCI) · PI: Brigitte C Widemann, M.D.
- RECRUITINGNCT06515860Neurofibromatosis Type 1 Tumor Early Detection StudyDavid Miller · PI: David T Miller, MD, PhD
- ACTIVE NOT RECRUITINGPhase 3NCT05913037FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform NeurofibromasShanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · PI: Wenbin Li, MD
- RECRUITINGN/ANCT04763109Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial IntelligenceNicole Baca · PI: Nicole Baca, MD
- ACTIVE NOT RECRUITINGPhase 1NCT05363267NF-1, Nutraceutical InterventionMasonic Cancer Center, University of Minnesota · PI: Christopher Moertel, MD
- ACTIVE NOT RECRUITINGN/ANCT05388370PASS of Paediatric Patients Initiating SelumetinibAstraZeneca
- ENROLLING BY INVITATIONNCT05238909Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1Ann & Robert H Lurie Children's Hospital of Chicago · PI: Carlos Prada, MD
- ACTIVE NOT RECRUITINGPhase 1NCT05309668Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PNAstraZeneca · PI: Study physician Study physician, MD
- RECRUITINGPhase 1NCT04750928Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical NeurofibromasNational Cancer Institute (NCI) · PI: Brigitte C Widemann, M.D.
- RECRUITINGPhase 2NCT05331105HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasShanghai Kechow Pharma, Inc. · PI: Hongqi Tian, Ph.D
- ACTIVE NOT RECRUITINGPhase 1NCT05101148Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform NeurofibromasAstraZeneca · PI: Study physician Study physician, MD
- ACTIVE NOT RECRUITINGN/ANCT05677594Multi-parametric Biomarker Development to Predict Malignant Conversion in Patients With Neurofibromatosis Type 1Johns Hopkins University · PI: Shivani Ahlawat, PhD
- ACTIVE NOT RECRUITINGN/ANCT05581511Natural History Study of Cutaneous Neurofibromas in People With NF1Johns Hopkins University · PI: Carlos G Romo, MD
- ACTIVE NOT RECRUITINGPhase 1NCT04954001Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
- ACTIVE NOT RECRUITINGPhase 1NCT04590235A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)AstraZeneca · PI: Qingfeng Li
- ACTIVE NOT RECRUITINGPhase 2NCT04481048Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1Children's Hospital Medical Center, Cincinnati · PI: Donald Gilbert, MD MS
- ACTIVE NOT RECRUITINGPhase 3NCT03871257A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade GliomaNational Cancer Institute (NCI) · PI: Jason R Fangusaro
- ACTIVE NOT RECRUITINGN/ANCT03820778Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1Children's National Research Institute · PI: Miriam Bornhorst, MD
- ACTIVE NOT RECRUITINGPhase 2NCT02964884Interventions for Reading Disabilities in NF1Vanderbilt University · PI: Laurie Cutting, PhD
- ACTIVE NOT RECRUITINGPhase 2NCT02407405MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasNational Cancer Institute (NCI) · PI: Brigitte C Widemann, M.D.
- ACTIVE NOT RECRUITINGPhase 1NCT01362803AZD6244 Hydrogen Sulfate for Children With Nervous System TumorsNational Cancer Institute (NCI) · PI: Brigitte C Widemann, M.D.
- RECRUITINGN/ANCT00598351Natural History Study of Patients With Neurofibromatosis Type 2National Institute of Neurological Disorders and Stroke (NINDS) · PI: Prashant Chittiboina, M.D.
- ACTIVE NOT RECRUITINGN/ANCT00924196Natural History Study of Patients With Neurofibromatosis Type INational Cancer Institute (NCI) · PI: Brigitte C Widemann, M.D.